Is insulin degludec a more effective treatment for patients using high doses of insulin glargine but not attaining euglycemia? Some case reports from India
Binayak Sinha,1 Kalyan Kumar Gangopadhyay,2 Samit Ghosal31Department of Endocrinology, AMRI Hospital, 2Department of Endocrinology, Fortis and Peerless Hospital, 3Nightingale Hospital, Kolkata, IndiaAbstract: Insulin therapy is not without side effects. In patients with complications on complex reg...
Guardado en:
Autores principales: | Sinha B, Gangopadhyay KK, Ghosal S |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/c3cd9b184ab64c96921aa90b80cc1f3b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Insulin degludec as an ultralong-acting basal insulin once a day: a systematic review
por: Wang F, et al.
Publicado: (2012) -
Long-term safety and efficacy of insulin degludec in the management of type 2 diabetes
por: Thuillier P, et al.
Publicado: (2015) -
Two-way crossover comparison of insulin glargine and insulin detemir in basal-bolus therapy using continuous glucose monitoring
por: Abe S, et al.
Publicado: (2011) -
Glargine and degludec: Solution behaviour of higher dose synthetic insulins
por: Gary G. Adams, et al.
Publicado: (2017) -
Immunogenicity and Efficacy of Insulin Glargine Biosimilar Ezelin versus Originator Insulin Glargine in Patients with Type 2 Diabetes
por: Tarigan TJE, et al.
Publicado: (2021)